7 Merrimack Pharmaceuticals Analyst Ratings, Earnings, Dividends and Insider Trades | $MACK | NASDAQ:MACK | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Merrimack Pharmaceuticals Company Profile (NASDAQ:MACK) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Merrimack Pharmaceuticals (NASDAQ:MACK) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 2 Hold Rating(s), 3 Buy Rating(s)Consensus Rating:Buy (Score: 2.60)Consensus Price Target: $11.00 (102.58% upside) Analysts' Ratings History for Merrimack Pharmaceuticals (NASDAQ:MACK) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare11/8/2013Brean CapitalBoost Price Target$14.00 -> $16.00View 8/9/2013Bank of AmericaDowngradeBuy -> Neutral$13.00 -> $6.00View 8/9/2013OppenheimerLower Price TargetOutperform$12.00 -> $10.00View 8/8/2013Cowen and CompanyDowngradeOutperform -> Market PerformView 7/22/2013UBS AGInitiated CoveragePositiveView 6/24/2013MizuhoInitiated CoverageBuy$12.00View 11/9/2012GuggenheimInitiated CoverageBuyView 9/27/2012Brean CapitalInitiated CoverageBuy$12.00View 8/31/2012Bank of AmericaInitiated CoverageBuy$13.00View 5/8/2012Cowen and CompanyInitiated CoverageOutperformView 5/8/2012OppenheimerInitiated CoverageOutperform$12.00View 5/8/2012JPMorgan Chase & Co.Initiated CoverageOverweight$10.00View (Data available from 3/10/2012 forward) Earnings History for Merrimack Pharmaceuticals (NASDAQ:MACK)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare2/27/2014($0.29)($0.33)ViewN/AView 11/7/2013($0.34)($0.39)ViewN/AView 8/8/2013Q2 2013($0.28)($0.31)$13.68 million$18.45 millionViewN/AView 3/14/2013Q4 2012($0.26)($1.76)$11.77 million$12.58 millionViewN/AView 11/14/2012Q312$0.00($1.81)$8.60 million$11.30 millionViewN/AView (Data available from 1/1/2011 forward) Dividend History for Merrimack Pharmaceuticals (NASDAQ:MACK)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Merrimack Pharmaceuticals (NASDAQ:MACK)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare12/17/2013Michael PorterDirectorBuy25,000$4.75$118,750.00View 12/12/2013William McclementsSVPBuy4,000$4.26$17,040.00View 12/10/2013Michael PorterDirectorBuy18,000$4.38$78,840.00View 12/6/2013James QuigleyDirectorBuy39,000$4.70$183,300.00View 12/4/2013Robert MulroyCEOBuy33,100$4.42$146,302.00View 12/3/2013Sarah NashDirectorBuy47,500$4.17$198,075.00View 12/2/2013William McclementsSVPBuy2,000$4.06$8,120.00View 11/29/2013Anthony SinskeyDirectorBuy3,800$3.92$14,896.00View 11/27/2013Gary CrockerDirectorBuy207,000$3.72$770,040.00View 12/14/2012John MendelsohnDirectorBuy5,000$6.63$33,150.00View 12/13/2012Gary L CrockerDirectorBuy36,500$6.77$247,105.00View 12/10/2012Michael E PorterDirectorBuy10,000$6.08$60,800.00View 9/14/2012Gary L CrockerDirectorBuy64,800$8.33$539,784.00View 8/24/2012James H QuigleyDirectorBuy12,500$7.55$94,375.00View (Data available from 1/1/2013 forward) About Merrimack Pharmaceuticals Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The Company's product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151. The Company's Network biology is an interdisciplinary approach to drug discovery and development that enables the Company to build functional and predictive computational models of biological systems based on quantitative, kinetic, multiplexed biological data. The Company provides its scientists with insights into how the complex molecular interactions that occur within cell signaling pathways, or networks, regulate cell decisions and how dysfunction within these networks leads to disease. As of June 31, 2011, the Company owned approximately 74% interest of Silver Creek. Headlines: (2/27) Merrimack Provides Fourth Quarter and Full Year 2013 Financial Results (2/18) Preclinical Study Results of Merrimack's MM-141 Published in Molecular Cancer Therapeutics (3/5) Should You Worry About the Short Interest in Merrimack (MACK)? (2/24) Merrimack to Present at the Cowen and Company 34th Annual Health Care Conference (2/20) Merrimack Announces Timing of Fourth Quarter 2013 Investor Conference Call (3/5) Should You Worry About the Short Interest in Merrimack (MACK)? - Tale of the Tape (3/3) MERRIMACK PHARMACEUTICALS To Present At Cowen & Co Conference;Webcast At 4:50PM Industry, Sector and Symbol: Sector: Healthcare Industry: Biotechnology Sub-Industry: Biotechnology Exchange: NASDAQ Symbol: MACK CUSIP: 59032810 Key Metrics: Previous Close: $5.4350 Day Moving Average: $5.2518200 Day Moving Average: $4.2614 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $611.0MCurrent Quarter EPS Consensus Estimate: $-1.14 EPS Additional Links: View MACK on Google FinanceView MACK on Yahoo FinanceView MACK's Company Profile on ReutersSearch for Merrimack Pharmaceuticals Inc. on Google Merrimack Pharmaceuticals (NASDAQ:MACK) Chart for Monday, March, 10, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.